TNFRSF9 and neoplasm: A previously published study demonstrated that transient DT given with systemic ɑ4-1BB agonist therapy led to severe immune-related adverse events (irAE) in MC38 tumor-bearing mice, further highlighting the advantages of our collagen-anchored ɑ4-1BB agonists63.